Skip to main content
Figure 1 | Health and Quality of Life Outcomes

Figure 1

From: Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients

Figure 1

Effect sizes of change in EQ-5D by responder status and treatment group. Change in effect size for EQ-5D when stratified by treatment group (dalfampridine-ER 20%-responder status or placebo) and 20%-responder status (≥20% percent increase in Timed 25-Foot Walk speed or < 20%) during on-treatment visits 3-6 and off treatment visits 7/8. A, B) results using North American-derived equation; C, D) results using United Kingdom-derived equation. *p < 0.05 versus D-ER nonresponders; †p < 0.05 versus placebo.

Back to article page

Health and Quality of Life Outcomes

ISSN: 1477-7525

Contact us